PARK8 (LRRK2) Antibody (L955)

Synthetic Peptide

Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

Polyclonal

120892

Purified Rabbit Polyclonal Antibody (Pab)

Tau-stable SY5Y cell image stained for endogenous LRRK (green) by
Abgent L955a (affinity purified), phosphorylated tau (red, monoclonal
AT8) and nuclear staining by DAPI.

1:10~50

WB

Park8 (LRRK2) Antibody (L955) (Cat. #AP7099h) western blot analysis in mouse lung tissue lysates (35ug/lane).This demonstrates the Park8 (LRRK2) antibody detected the Park8 (LRRK2) protein (arrow).

1:1000

Rabbit Ig

930-961

This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 930-961 amino acids from human PARK8(LRRK2).